Santen Pharmaceutical Co Stock Today
| SNPHF Stock | USD 10.15 0.09 0.88% |
Performance0 of 100
| Odds Of DistressLess than 45
|
Santen Pharmaceutical is trading at 10.15 as of the 25th of November 2024. This is a 0.88 percent decrease since the beginning of the trading day. The stock's lowest day price was 10.15. Santen Pharmaceutical has 45 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Santen Pharmaceutical Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2024 and ending today, the 25th of November 2024. Click here to learn more.
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. The company has 388.22 M outstanding shares. More on Santen Pharmaceutical Co
Moving together with Santen Pink Sheet
Moving against Santen Pink Sheet
| 0.45 | STI | Solidion Technology Symbol Change | PairCorr |
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Santen Pink Sheet Highlights
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Santen Pharmaceutical Co [SNPHF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.95 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Santen Pharmaceutical's market, we take the total number of its shares issued and multiply it by Santen Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Santen Pharmaceutical classifies itself under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 388.22 M outstanding shares.
Santen Pharmaceutical Co has accumulated about 69.53 B in cash with 46.04 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 176.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Santen Pharmaceutical Probability Of Bankruptcy
Ownership AllocationSanten Pharmaceutical shows a total of 388.22 Million outstanding shares. Over half of Santen Pharmaceutical's outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Santen Ownership Details
Santen Pharmaceutical Risk Profiles
| Mean Deviation | 0.7385 | |||
| Standard Deviation | 1.79 | |||
| Variance | 3.19 | |||
| Risk Adjusted Performance | (0.07) |
Santen Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Santen Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sign In To Macroaxis Now
Sign In To MacroaxisSign in to explore Macroaxis' wealth optimization platform and fintech modules |
| All Next | Launch Module |
Santen Pharmaceutical Corporate Management
| Nobuko Kato | Chief Officer | Profile | |
| Mika Masunari | G Officer | Profile | |
| Nikolas Tripodis | Chief Officer | Profile | |
| Kaori Itagaki | Gen Group | Profile |
Other Information on Investing in Santen Pink Sheet
Santen Pharmaceutical financial ratios help investors to determine whether Santen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santen with respect to the benefits of owning Santen Pharmaceutical security.